+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antithrombotic Drugs Market by Drug Class (Anticoagulants, Antiplatelets, Thrombolytics), Indication (Atrial Fibrillation, Deep Vein Thrombosis, Myocardial Infarction), Route Of Administration, End User - Global Forecast 2025-2030- Product Image
Antithrombotic Drugs Market by Drug Class (Anticoagulants, Antiplatelets, Thrombolytics), Indication (Atrial Fibrillation, Deep Vein Thrombosis, Myocardial Infarction), Route Of Administration, End User - Global Forecast 2025-2030- Product Image
Sale

Antithrombotic Drugs Market by Drug Class (Anticoagulants, Antiplatelets, Thrombolytics), Indication (Atrial Fibrillation, Deep Vein Thrombosis, Myocardial Infarction), Route Of Administration, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 185 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6013888
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The antithrombotic drugs market is advancing rapidly, supported by shifts in therapy approaches, regulatory policy, and digital integration. Senior leaders must align with these multidimensional changes to capitalize on transformation within this competitive landscape.

Market Snapshot: Antithrombotic Drugs Market Size & Growth

The Antithrombotic Drugs Market grew from USD 42.47 billion in 2024 to USD 45.15 billion in 2025. It is expected to continue growing at a CAGR of 6.06%, reaching USD 60.49 billion by 2030.

Scope & Segmentation: In-Depth Analysis of Antithrombotic Therapies

This comprehensive study segments and evaluates the antithrombotic drugs market across several dimensions, offering strategic clarity for industry stakeholders:

  • Drug Classes: Anticoagulants, including direct oral anticoagulants, direct thrombin inhibitors (dabigatran), factor Xa inhibitors (apixaban, edoxaban, rivaroxaban), heparins (low molecular weight and unfractionated), vitamin K antagonists; antiplatelets; thrombolytics.
  • Therapeutic Indications: Atrial fibrillation, deep vein thrombosis, myocardial infarction, pulmonary embolism, stroke prevention.
  • Route of Administration: Oral tablets and parenteral injections.
  • End Users: Home care patients, hospitals, retail pharmacies.
  • Geographic Regions: Americas (with detailed coverage of the United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including the United Kingdom, Germany, France, Russia, and others), and Asia-Pacific (featuring China, India, Japan, Australia, South Korea, and select Southeast Asian markets).
  • Key Companies: Bayer Aktiengesellschaft, Pfizer Inc., Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Johnson & Johnson, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, Novartis AG, Merck & Co., Inc.

Key Takeaways: Strategic Insights for Decision-Makers

  • Direct oral anticoagulants now dominate new prescription trends, favored for their clinical reliability and minimal monitoring compared to traditional therapies.
  • Regulatory acceleration and digital health integration are optimizing patient adherence and enabling more streamlined care delivery models worldwide.
  • Regional diversity in healthcare infrastructure, especially across emerging Asian and African markets, creates distinct opportunities and access challenges.
  • Consolidation in the generics sector is increasing, as providers seek to offset tariff-induced pressures and evolving procurement practices.
  • Strategic collaborations and portfolio diversification remain critical, with leading firms extending reach through licensing and regional partnerships to serve both premium and cost-sensitive markets.

Tariff Impact: Implications for Supply Chains and Pricing

Recent tariff measures in the U.S. introduced additional complexity for antithrombotic drug supply chains, escalating active ingredient costs and prompting shifts in both sourcing and manufacturing strategies. Brand manufacturers managed some pricing stability, while generic producers faced tighter margins and industry consolidation. Healthcare institutions responded with diversified procurement and volume-based agreements to maintain supply continuity and cost control, driving investments in local production and alternative supply networks.

Technology Integration Across Patient Pathways

AI-based dose optimization platforms and remote monitoring solutions are driving value-based care in antithrombotic management. These advancements enhance patient adherence, support risk stratification, and inform clinical decision-making, positioning stakeholders for efficiency gains and differentiation in a competitive environment.

Methodology & Data Sources

This report is built upon primary expert interviews with key opinion leaders, clinical specialists, and senior executives, combined with comprehensive reviews of peer-reviewed journals, industry publications, patent filings, and government data. Robust triangulation and analytical modeling ensure accuracy and practical relevance throughout the research.

Why This Report Matters

  • Enables decision-makers to understand emerging therapeutic models, navigate procurement complexities, and identify competitive threats across regions.
  • Supports strategic portfolio planning by providing actionable segmentation with attention to technology, regional, and regulatory drivers.
  • Guides informed decisions for investment, partnership, and operational resilience in a changing market environment.

Conclusion

The antithrombotic drugs market is undergoing sustained evolution, shaped by scientific, regulatory, and economic trends. Leaders equipped with comprehensive insights can adapt strategies for greater resilience, innovation, and patient-centric focus in this dynamic sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of Factor Xa inhibitors in expanding indications such as peripheral artery disease and post-stent thrombosis prevention
5.2. Impact of emerging direct thrombin inhibitors with oral formulations on patient adherence in atrial fibrillation
5.3. Adoption of precision medicine approaches to tailor antithrombotic therapy based on pharmacogenomic profiling
5.4. Increased competition from biosimilar low molecular weight heparins driving price erosion in hospital procurement
5.5. Integration of digital health monitoring solutions for real-time anticoagulation management and dosing adjustments
5.6. Development of reversible antidotes for novel oral anticoagulants to mitigate bleeding risk in emergency settings
5.7. Rising use of dual pathway inhibition regimens combining low-dose anticoagulants with antiplatelet agents in high-risk cardiovascular patients
5.8. Expansion of clinical trial pipelines investigating novel factor XI and XII inhibitors for lower bleeding risk profiles
5.9. Regulatory shifts favoring expedited review pathways for breakthrough antithrombotic therapies to address unmet stroke prevention needs
5.10. Growing market penetration of long-acting subcutaneous anticoagulant formulations enabling reduced dosing frequency in chronic care settings
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antithrombotic Drugs Market, by Drug Class
8.1. Introduction
8.2. Anticoagulants
8.2.1. Direct Oral Anticoagulants
8.2.1.1. Direct Thrombin Inhibitors
8.2.1.1.1. Dabigatran
8.2.1.2. Factor Xa Inhibitors
8.2.1.2.1. Apixaban
8.2.1.2.2. Edoxaban
8.2.1.2.3. Rivaroxaban
8.2.2. Heparins
8.2.2.1. Low Molecular Weight Heparin
8.2.2.2. Unfractionated Heparin
8.2.3. Vitamin K Antagonists
8.3. Antiplatelets
8.4. Thrombolytics
9. Antithrombotic Drugs Market, by Indication
9.1. Introduction
9.2. Atrial Fibrillation
9.3. Deep Vein Thrombosis
9.4. Myocardial Infarction
9.5. Pulmonary Embolism
9.6. Stroke Prevention
10. Antithrombotic Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Oral
10.2.1. Tablet
10.3. Parenteral
10.3.1. Injection
11. Antithrombotic Drugs Market, by End User
11.1. Introduction
11.2. Home Care
11.3. Hospital
11.4. Retail Pharmacy
12. Americas Antithrombotic Drugs Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Antithrombotic Drugs Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Antithrombotic Drugs Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Bayer Aktiengesellschaft
15.3.2. Pfizer Inc.
15.3.3. Bristol-Myers Squibb Company
15.3.4. Sanofi S.A.
15.3.5. AstraZeneca PLC
15.3.6. Johnson & Johnson
15.3.7. Boehringer Ingelheim International GmbH
15.3.8. Daiichi Sankyo Company, Limited
15.3.9. Novartis AG
15.3.10. Merck & Co., Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. ANTITHROMBOTIC DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ANTITHROMBOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. ANTITHROMBOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. ANTITHROMBOTIC DRUGS MARKET: RESEARCHAI
FIGURE 24. ANTITHROMBOTIC DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 25. ANTITHROMBOTIC DRUGS MARKET: RESEARCHCONTACTS
FIGURE 26. ANTITHROMBOTIC DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTITHROMBOTIC DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DABIGATRAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DABIGATRAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APIXABAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APIXABAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY EDOXABAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY EDOXABAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RIVAROXABAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RIVAROXABAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY STROKE PREVENTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY STROKE PREVENTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 131. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 132. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 133. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 134. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 135. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 136. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 137. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 138. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 139. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 140. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 141. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
TABLE 142. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2030 (USD MILLION)
TABLE 143. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 144. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 145. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 148. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 149. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 150. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 151. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 154. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 155. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 156. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 157. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 158. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 159. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 160. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 161. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 162. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 163. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
TABLE 164. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2030 (USD MILLION)
TABLE 165. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 166. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 167. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 168. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 169. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 170. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 171. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 172. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 173. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 244. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 246. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 248. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 250. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
TABLE 254. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 256. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 260. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 262. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 266. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 267. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 268. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 269. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 270. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 271. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 272. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 273. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 274. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 275. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
TABLE 276. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2030 (USD MILLION)
TABLE 277. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 278. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 279. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 280. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 281. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 282. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 283. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 284. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 285. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 288. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 289. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 290. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 291. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 292. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 293. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 294. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 295. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 296. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 297. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
TABLE 298. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2030 (USD MILLION)
TABLE 299. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 300. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 301. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 302. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 303. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 304. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 305. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 306. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 307. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 308. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 309. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 310. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 311. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 312. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 313. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
TABLE 314. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2030 (USD MILLION)
TABLE 315. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 316. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 317. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 318. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 319. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
TABLE 320. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2030 (USD MILLION)
TABLE 321. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 322. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 323. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 324. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 325. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 326. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 327. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 328. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 329. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 330. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY E

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Antithrombotic Drugs market report include:
  • Bayer Aktiengesellschaft
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Sanofi S.A.
  • AstraZeneca PLC
  • Johnson & Johnson
  • Boehringer Ingelheim International GmbH
  • Daiichi Sankyo Company, Limited
  • Novartis AG
  • Merck & Co., Inc.

Table Information

Report AttributeDetails
No. of Pages185
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 45.15 Billion
Forecasted Market Value ( USD ) by 2030 $ 60.49 Billion
Compound Annual Growth Rate6.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Antithrombotic Drugs - Global Strategic Business Report - Product Image

Antithrombotic Drugs - Global Strategic Business Report

  • Report
  • 282 Pages
  • Global
From
Factor XI Inhibitors - Pipeline Insight, 2025 - Product Image

Factor XI Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Intracranial Hemorrhage - Pipeline Insight, 2025 - Product Image

Intracranial Hemorrhage - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Argatroban Market by Indication (Heparin Induced Thrombocytopenia, Percutaneous Coronary Intervention), End User (Ambulatory Surgical Center, Hospital), Product Type, Distribution Channel, Application - Global Forecast 2025-2030 - Product Image

Argatroban Market by Indication (Heparin Induced Thrombocytopenia, Percutaneous Coronary Intervention), End User (Ambulatory Surgical Center, Hospital), Product Type, Distribution Channel, Application - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Apixaban - Global Strategic Business Report - Product Image

Apixaban - Global Strategic Business Report

  • Report
  • 282 Pages
  • Global
From

About the Antithrombotics Market

Antithrombotics are drugs used to prevent the formation of blood clots, which can lead to cardiovascular diseases such as stroke and heart attack. These drugs work by inhibiting the activity of clotting factors in the blood, thus preventing the formation of clots. Common antithrombotics include aspirin, clopidogrel, warfarin, and heparin. Aspirin is the most widely used antithrombotic, and is often prescribed to reduce the risk of stroke and heart attack. Clopidogrel is used to prevent blood clots in patients with coronary artery disease, while warfarin is used to prevent and treat blood clots in patients with atrial fibrillation. Heparin is used to prevent and treat deep vein thrombosis and pulmonary embolism. The antithrombotics market is highly competitive, with many large pharmaceutical companies offering a range of products. Some of the major players in the market include Bayer, Pfizer, Sanofi, Bristol-Myers Squibb, and Merck. These companies are continuously developing new products to meet the needs of patients and healthcare providers. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.